3 Biggest Biotech Crashes in March

Here's why Celldex (CLDX), Acceleron (XLRN), and Newlink (NLNK) all tumbled in March.

Apr 3, 2014 at 6:30PM

March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking. Celldex Therapeutics (NASDAQ:CLDX), Acceleron (NASDAQ:XLRN), and Newlink Genetics (NASDAQ:NLNK) all tumbled more than 25% last month -- far more than the 10% drop in the iShares NASDAQ Biotechnology Index (NASDAQ:IBB) ETF.

However, big pops and drops aren't uncommon in biotech, so let's consider the catalysts that drove shares lower and see whether shares may bounce back.

CLDX Chart

CLDX data. Source: YCharts.

Using the body to fight cancer
It shouldn't surprise biotech investors when highfliers fall back to earth, yet that's what seems to have happened at Celldex, one of biotechnology's biggest winners last year.

Excitement over Celldex's gene targeting immunotherapies sent shares rocketing more than 200% higher last year. However, profit takers sent Celldex shares reeling by nearly 40% in March.

Celldex is further along in clinical trials than many of last year's top-performing biotechs. Its lead drug is rindopepimut, a phase 3 therapy for a rare form of brain cancer known as glioblastoma. In December, Celldex updated results from rindopepimut's previous phase 2 trial, showing that 51% of those treated with the drug survived two years. That was far better than the 6% rate typical for the disease.

In addition to rindopepimut, Celldex is using technology from Seattle Genetics in CDX-011, a breast cancer drug that's in phase 2. CDX-011 received the Food and Drug Administration's fast-track designation back in 2010 following solid results in phase 1/2 studies.

Since Celldex has two promising compounds quickly making their way through clinic, you're right to wonder why shares dropped. It could be investors simply got a little ahead of the potential to commercialize rindopepimut given the phase 3 trial isn't expected to complete enrollment until halfway through this year. If so, that would put interim data in front of investors either late this year or early in 2015. More likely, rolling markets encouraged investors with big gains to ring the register and lock in profit. After all, any number of things can derail even the most promising drugs in trials.

Boosting red blood cells to battle anemia
Acceleron's roller-coaster returns are another example of the volatility associated with investing in emerging biotech stocks. After its initial public offering last fall, shares in the company took off, jumping 170% into year-end. However, stalling markets caused shares to slump 26% in March.

Investors who sold into that drop were probably shaking their heads when shares spiked 13% on April 2 after Celgene (NASDAQ:CELG) agreed to buy 1.1 million shares for $47 million. Since Celgene already owned 3.5 million shares in Acceleron heading into this latest purchase, its ownership stake is now just shy of 15%. That's a big vote of confidence.

The two companies began their relationship in 2008 when Celgene agreed to collaborate on Sotatercept, a red blood cell boosting compound for diseases including myelodysplastic syndromes, chronic kidney disease, and multiple myeloma.

Most recently, Sotatercept entered phase 2 as an anemia treatment for end stage kidney disease in December, triggering a $7 million milestone payment. However, that payment is a pittance compared to the $360 million Celgene may eventually pay Acceleron in regulatory and commercial milestones.

Acceleron has seven studies ongoing for Sotatercept, including a phase 2 multiple myeloma trial that reached its primary completion date for collecting data in February. Investors will have to wait longer for insight into the just-launched Sotatercept trial for end-stage kidney disease given its primary completion date isn't until September 2015.

Wait-and-see mode
Similar to Celldex, Newlink is working on immunotherapies for cancer, but unlike Celldex, Newlink reported somewhat disappointing news on one of its clinical compounds in March. That sent shares tumbling 36% last month after more than doubling in January and February.

Investors were apparently hoping independent monitors would halt Newlink's ongoing phase 3 trial of algenpantucel-L for pancreatic cancer in March when it reviewed interim results, but monitors recommended the trial continue to its completion date instead.

The monitors will take another look at data once 333 patient events occur (this one came after 222 events), and if they decide to continue again the final data will be digested at 444 events. That leaves investors with nothing but question marks for now.

Foolworthy final thoughts
If you're going to invest in biotech, you're going to need pretty thick armor, especially if you're going to venture into clinical-stage companies. Shares in emerging biotech are heavily dependent on the news of the day, which makes them particularly boom and bust.

Since investors tend to overreach on both the way up and on the way down, there may be an opportunity in these companies, but only for the most speculative, risk-taking investor. Otherwise, investors should stay on the sidelines until these companies mature or look for opportunities elsewhere.

Including this one stock that could be a better bet this year
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Todd Campbell owns Celgene. He owns E.B.Capital Markets, LLC, whose clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC, whose clients do not have positions in the companies mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers